Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Danaher : Unit's SARS-CoV-2 IgM Antibody Test Gets FDA Emergency Use OK

10/09/2020 | 08:31am EST

By Colin Kellaher

Danaher Corp.'s Beckman Coulter unit on Friday said its Access SARS-CoV-2 IgM assay received U.S. Food & Drug Administration emergency-use authorization.

Beckman Coulter said the test, which detects antibodies that recognize the receptor binding domain of the spike protein that the SARS-CoV-2 virus uses to enter the human host cells, demonstrates 99.9% specificity and 98.3% sensitivity.

Beckman Coulter said the test is part of a suite of diagnostic solutions it is developing in response to the coronavirus pandemic.

The company previously received FDA emergency-use authorization for its Access SARS-CoV-2 IgG assay and its interleukin 6 assay, which can be used to assist in identifying severe inflammatory response in patients with confirmed Covid-19 illness.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-09-20 0830ET

All news about DANAHER CORPORATION
11/25DANAHER : to Present at Evercore ISI HealthCONx Conference
AQ
11/24DANAHER : To Present At Evercore ISI HealthCONx Conference
PR
11/23DANAHER : Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antib..
PR
11/17DANAHER : to Present at Wolfe Research Healthcare Conference
AQ
11/16DANAHER : To Present At Wolfe Research Healthcare Conference
PR
11/11DANAHER : Releases 2020 Sustainability Report
AQ
11/10DANAHER : Releases 2020 Sustainability Report
PR
11/10DANAHER : Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries..
PR
10/27DANAHER : Cytiva strengthens support to diagnostics industry with new labs, serv..
AQ
10/23DANAHER : Reports Third Quarter 2020 Results
AQ
More news
Financials (USD)
Sales 2020 21 959 M - -
Net income 2020 3 386 M - -
Net Debt 2020 16 005 M - -
P/E ratio 2020 48,2x
Yield 2020 0,32%
Capitalization 160 B 160 B -
EV / Sales 2020 8,01x
EV / Sales 2021 6,80x
Nbr of Employees 60 000
Free-Float 74,1%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 250,95 $
Last Close Price 225,00 $
Spread / Highest target 24,4%
Spread / Average Target 11,5%
Spread / Lowest Target -38,7%
EPS Revisions
Managers
NameTitle
Rainer M. Blair President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Alan G. Spoon Independent Director
Walter G. Lohr Independent Director
Sector and Competitors